The Weekly Five | 9–15 November

Five studies worth your time this week, spanning brain metastases, Merkel cell carcinoma, nutritional support, breast radiotherapy and prostate SBRT.

1. ROADS phase III: GammaTile improves surgical bed control after brain metastasis resection

In 204 patients, intraoperative cesium-131 GammaTile reduced 12-month surgical bed recurrence to 1.3% versus 15.4% with postoperative stereotactic RT. Radiation necrosis rates were similar, although longer follow-up is needed to establish late safety and survival benefits.

Read post

2. ESTRO publishes new radiotherapy guidance for Merkel cell carcinoma

The new ESTRO guideline recommends 60 Gy in 30 fractions for definitive treatment and at least 50 Gy in 25 fractions postoperatively. It also addresses target margins, timely treatment, and risk-adapted nodal irradiation, providing practical guidance for this rare malignancy.

Read post

3. Early nutritional supplementation reduces weight loss during nasopharyngeal chemoradiotherapy

In a randomized trial involving 216 evaluable patients, starting nutritional supplementation at the beginning of chemoradiotherapy reduced >5% weight loss from 80.7% to 65.4%. Grade ≥3 oral mucositis was also less frequent (14.0% vs 26.6%).

Read post

4. HARVEST phase III: three-week regional nodal irradiation shows comparable acute toxicity

In 801 patients with node-positive breast cancer, 40.05 Gy in 15 fractions produced similar overall acute toxicity to 50 Gy in 25 fractions, including comprehensive internal mammary irradiation. Moderate dermatitis was less frequent with hypofractionation, while the primary locoregional recurrence endpoint remains pending.

Read post

5. SRAM: pelvic prostate SBRT worsens patient-reported bowel function despite similar physician-graded toxicity

In 121 evaluable high-risk prostate cancer patients, once-weekly pelvic SBRT produced similar grade ≥2 gastrointestinal toxicity to conventional IMRT (16.7% vs 13.1%). However, one-year patient-reported bowel scores were significantly worse (82.5 vs 90.1), highlighting a toxicity signal not fully captured by physician grading.

Read post

That's the week. See you next Sunday.

Browse more research Suggest a correction